The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model.

Abstract

BACKGROUND AND OBJECTIVE:

Community-acquired bacterial pneumonia (CABP) affects millions of people each year in the USA. The majority of patients with CABP are treated in the community setting with empirical antimicrobial therapy. Delafloxacin is an anionic fluoroquinolone approved for the treatment of adult patients with CABP. This de novo analysis sought to estimate the budget impact of delafloxacin in the treatment of adult patients with CABP in the outpatient setting from the payer's perspective.

METHODS:

A budget impact model (BIM) was developed from the perspective of a US third-party payer to estimate the cost of introducing delafloxacin for the outpatient treatment of CABP over a 1-year time horizon. Population, clinical, and cost inputs were based on the available literature, clinical trial data, and real-world evidence studies. Scenario analyses were conducted to evaluate the potential budget impact among COPD/asthma patients based on the findings from the phase III trial of delafloxacin for CABP, which indicated that patients with COPD or asthma may experience improved effectiveness with delafloxacin compared to moxifloxacin.

RESULTS:

In the base-case analysis, with a hypothetical plan of 1,000,000 members, the model estimated that adding delafloxacin to the formulary resulted in a total budget impact of $58,987. This increase was mainly attributed to treatment acquisition costs. In the scenario analysis that was restricted to COPD/asthma patients, adding delafloxacin to the formulary was estimated to result in a total budget impact of $5,042.

CONCLUSION:

The results of the budget impact analyses provide conservative estimates of the impact of adding delafloxacin to outpatient formularies in substitution of moxifloxacin.

• Authors: Thomas P Lodise, Glenn S Tillotson, Andrew Spargo, Duygu Bozkaya, Jill Massey
• Journal: Clinical drug investigation (Clin Drug Investig) Vol. 40 Issue 10 Pg. 961-971 (Oct 2020) ISSN: 1179-1918 [Electronic] New Zealand
• PMID: 32651832 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• Fluoroquinolones
• delafloxacin
• Moxifloxacin

Topics

• Adult
• Anti-Bacterial Agents (economics, therapeutic use)
• Community-Acquired Infections (drug therapy)
• Drug Costs
• Fluoroquinolones (economics, therapeutic use)
• Humans
• Models, Economic
• Moxifloxacin
• Outpatients
• Pneumonia, Bacterial (drug therapy)